EX-2.2 4 a2119736zex-2_2.htm EX-2.2 QuickLinks -- Click here to rapidly navigate through this document MASTER AGREEMENT by and among METABASIS THERAPEUTICS, INC., SICOR INC. and JOHN BECK, MARK ERION & PAUL K. LAIKIND June 30, 1999 MASTER AGREEMENT
Exhibit 2.2
by and among
METABASIS THERAPEUTICS, INC.,
SICOR INC.
and
XXXX XXXX, XXXX XXXXX & XXXX X. XXXXXXX
June 30, 1999
THIS MASTER AGREEMENT (the "Agreement") is made as of June 30, 1999 by and among METABASIS THERAPEUTICS, INC., a Delaware corporation (the "Company"), SICOR INC. (formerly Gensia Sicor Inc.), a Delaware corporation ("SICOR"), and XXXX XXXX, XXXX XXXXX and XXXX X. XXXXXXX (each a "Senior Manager" and collectively, the "Senior Managers"). The Company, SICOR, and the Senior Managers are hereinafter also referred to individually as a "Party" and collectively as the "Parties."
THE PARTIES HEREBY AGREE AS FOLLOWS:
1. Purchase and Sale of Stock.
1.1 Sale and Issuance of Common Stock.
(a) The Company shall adopt and file with the Secretary of State of the State of Delaware on or before the Closing (as defined below) the Amended and Restated Certificate of Incorporation in the form attached hereto as Exhibit A (the "Restated Certificate").
(b) Subject to the terms and conditions of this Agreement, each Senior Manager will purchase, and the Company will sell and issue to such Senior Manager, at the Closing that number of shares of the Company's Common Stock set forth opposite such Senior Manager's name on Schedule 1.1(b) hereto for the purchase price of $.05 per share of Common Stock, such purchase price to be paid at the Closing in cash and promissory notes as set forth on such Schedule 1.1(b) (the "Purchase Price"), pursuant to and in accordance with the Common Stock Purchase Agreement attached hereto as Exhibit B (the "Purchase Agreement").
Transition Services Agreement will terminate and be of no further force and effect. The Company and SICOR acknowledge that the Transition Services Agreement was extended beyond the December 31, 1998 expiration date and has been in full force and effect until the termination pursuant to this subsection. The Company will deliver to SICOR at the Closing a promissory note, payable to SICOR, in the principal amount of $480,409 (reimbursement due to SICOR by the Company under such agreement) in the form attached hereto as Exhibit C (the "Note").
(c) Termination of Severance Agreements. The following severance agreements shall terminate:
- (i)
- Severance Agreement dated as of October 1995 between Xxxx X. Xxxxxxx and SICOR, as amended, and
- (ii)
- Severance Agreement dated as of October 1995 between Xxxx X. Xxxxx and SICOR, as amended.
(d) Post-Closing Royalties. The Company hereby agrees to pay to SICOR royalties in the amount of (i) two percent (2%) of Net Sales of any product by the Company or its affiliates the manufacture, use, sale, or import of which would infringe a claim of an issued, valid and unexpired patent or a claim of a patent application, in each case, that currently exists or is based on any existing patents, patent applications, discoveries or inventions of the Company as of the date of the Closing, (collectively, the "Patent Technology"), and ten percent (10%) of any royalties received by the Company or its affiliates from any licenses granted to a third party by the Company or its affiliates to the Patent Technology; or (ii) one percent (1%) of Net Sales of any product by the Company which uses, incorporates or is based on information, trade secrets, know-how and other proprietary rights of the Company as of the date of the Closing, other than any Patent Technology (collectively, the "Know-How"), and five percent (5%) of any royalties received by the Company or its affiliates from any licenses granted to a third party by the Company or its affiliates to the Know-How. To the extent that the Company may have to pay royalties under both subsections (d)(i) and (d)(ii) of this Section for any product or third-party license, the Company only shall pay royalties under subsection (d)(i) for such product and third-party license. Notwithstanding the foregoing, to the extent that the Company is obligated to pay royalties to SICOR on sales of products and third party royalties relating to certain technology pursuant to the License Agreement (as defined in Section 5.12 below), then the Company shall not owe SICOR royalties pursuant to this Section 1.3(d). "Net Sales" means, with respect to any product, the invoiced sales price of such product billed to independent customers who are not affiliates, less (a) credits, allowances, discounts and rebates to, and chargebacks from the account of such independent customers for spoiled, damaged, out-dated rejected or returned product; (b) actual freight and insurance costs incurred in transporting such product to such customers which are separately invoiced to such customers; (c) cash, quantity and trade discounts and other price reductions; (d) sales, use, value-added and other direct taxes incurred; and (e) customs duties, surcharges and other governmental charges incurred in connection with the exportation or importation of such product.
2
by law to be deducted in respect of such sales and licenses. With respect to sales of products invoiced in United States dollars, the gross sales, Net Sales and royalties payable shall be expressed in United States dollars. With respect to sales of such products invoiced in a currency other than United States dollars, the gross sales, Net Sales and royalties payable shall be expressed in the domestic currency of the party making the sale together with the United States dollar equivalent of the royalty payable, calculated using the average closing buying rate for such currency quoted in the continental terms method of quoting exchange rates (local currency per US$1) by Bank of America NT&SA in London, England on each of the last business day of each month in the quarter prior to the date of payment. Reports shall be due on the sixtieth (60th) day following the close of each quarter. The Company shall keep complete and accurate records in sufficient detail to properly reflect all gross sales, Net Sales and third party licenses and to enable the royalties payable hereunder to be determined.
(f) Payment Terms. Royalties shown to have accrued by each royalty report provided for under Section 1.3(e) above shall be due on the date such royalty report is due. Payment of royalties in whole or in part may be made in advance of such due date.
(A) Upon the written request of SICOR and not more than once in each calendar year, the Company shall permit an independent certified public accounting firm of nationally recognized standing selected by SICOR and reasonably acceptable to the Company, at SICOR's expense, to have access during normal business hours to such of the records of the Company as may be reasonably necessary to verify the accuracy of the royalty reports hereunder for any year ending not more than twenty-four (24) months prior to the date of such request. The accounting firm shall disclose to SICOR only whether the reports are correct or not and the specific details concerning any discrepancies. No other information shall be shared.
(B) If such accounting firm concludes that additional royalties were owed during such period, the Company shall pay the additional royalties within thirty (30) days of the date SICOR delivers to the Company such accounting firm's written report so concluding. If such accounting firm concludes that the Company overpaid royalties during such period, SICOR shall refund the amount of such overpayment within thirty (30) days of the date such accounting firm delivers its written report so concluding to SICOR. The fees charged by such accounting firm shall be paid by SICOR; provided, however, if the audit correctly discloses that the royalties payable by the Company for the audited period are more than one hundred ten percent (110%) of the royalties actually paid for such period, then the Company shall pay the reasonable fees and expenses charged by such accounting firm.
(C) SICOR shall treat all financial information subject to review under this subsection 1.3(g) as confidential, and shall cause its accounting firm to retain all such financial information in confidence.
3
Adverse Effect. "Transaction Documents" means this Agreement, the Note, the License Agreement, the Amended and Restated Sublease Agreement, the Amendment to Investor Rights Agreement, the Amended and Restated Research and Development Agreement, the Purchase Agreements, the Loan Agreement and the Restated Certificate (including in each case all exhibits and schedules thereto). "Material Adverse Effect" means a material adverse effect on the condition (financial or otherwise), assets relating to, or results of operations of the Company's business, as presently conducted and proposed to be conducted.
(a) Preferred Stock. 13,851,939 shares of preferred stock, par value $.001 per share (the "Preferred Stock"), 851,939 of which have been designated Series A Preferred Stock (the "Series A Preferred Stock"), of which 851,939 are issued and outstanding, and 10,000,000 of which have been designated Subordinated Convertible Preferred Stock (the "Subordinated Preferred Stock"), all of which are outstanding, and 3,000,000 of which have been designated Series B Preferred Stock, of which none are issued and outstanding. Immediately following the Closing, an aggregate of 1,703,878 shares of Common Stock will be issuable upon conversion of the Series A Preferred Stock owned by Sankyo Company, Ltd., a Japanese corporation ("Sankyo") and have been reserved by all necessary corporate action. The rights, preferences and privileges of the Series A Preferred Stock, the Series B Preferred Stock and Subordinated Preferred Stock are as stated in the Restated Certificate. Shares of Common Stock issuable upon conversion of the Series A Preferred Stock, the Series B Preferred Stock and the Subordinated Preferred Stock have been reserved by all necessary corporate action.
(b) Common Stock. 26,000,000 shares of common stock, par value $.001 per share (the "Common Stock"), 1,000 of which are issued and outstanding and owned by SICOR.
All shares of Common Stock, including without limitation the Shares, and Preferred Stock issued and outstanding immediately prior to or issued concurrently with the Closing have been duly authorized and have been or will be, as the case may be, validly issued in accordance with all applicable U.S. federal and state securities laws and are or, upon issuance will be, fully paid and nonassessable.
4
bound. To the knowledge of its officers, the Company is not in violation or default of any instrument or contract to which it is a party or by which it is bound or, to the knowledge of its officers after reasonable inquiry, of any provision of any federal or state statute (including without limitation environmental and labor laws and filing requirements under the Employee Retirement Income Security Act of 1974 ("ERISA")), rule or regulation applicable to the Company, which violation or default would have a Material Adverse Effect. The execution, delivery and performance of this Agreement and the other Transaction Documents and the consummation of the transactions contemplated hereby and thereby will not result in any such violation or be in conflict with or constitute, with or without the passage of time and giving of notice, either a default under any such provision, instrument, judgment, order, writ, decree or contract or an event which results in the creation of any material lien, charge or encumbrance upon any assets of the Company.
(a) Except for the agreements explicitly contemplated hereby, there are no agreements, understandings or proposed transactions between the Company and any of its officers, directors, affiliates or any affiliate thereof.
(b) There are no agreements, understandings, instruments, contracts or proposed transactions to which the Company is a party or by which it is bound which involve (i) obligations (contingent or otherwise) of, or payments to the Company in excess of, $25,000, (ii) the license of any patent, copyright, trade secret or other proprietary right of the Company or (iii) any other material obligation.
(c) The Company has not (i) declared or paid any dividends, or authorized or made any distribution upon or with respect to any class or series of its capital stock, (ii) incurred any indebtedness for money borrowed or incurred any other liabilities individually in excess of $25,000 or in excess of $100,000 in the aggregate, (iii) made any loans or advances to any person, other than ordinary advances for travel expenses or (iv) sold, exchanged or otherwise disposed of any of its assets or rights, other than the sale of its inventory in the ordinary course of business.
(d) The Company has not engaged in the past three (3) months in any discussion (i) with any representative of any corporation or corporations regarding the consolidation or merger of the Company with or into any such corporation or corporations, (ii) with any corporation, partnership, association or other business entity or any individual regarding the sale, conveyance or disposition of all or substantially all of the assets of the Company or a transaction or series of related transactions in which more than fifty percent (50%) of the voting power of the Company is disposed of, other than as contemplated by this Agreement, or (iii) regarding any other form of liquidation, dissolution or winding up of the Company.
(e) For the purposes of subsections (b) and (c) above, all indebtedness, liabilities, agreements, understandings, instruments, contracts and proposed transactions involving the same person or entity (including persons or entities the Company has reason to believe are affiliated) shall be aggregated for the purpose of meeting the individual minimum dollar amounts of such subsections.
5
(f) The Company has delivered to SICOR a true and complete copy of each agreement listed on the Schedule of Exceptions.
(a) Each employee and consultant of the Company has executed a Proprietary Information and Inventions Agreement in the forms attached hereto as Exhibit D. The Company, after reasonable investigation, is not aware that any employee, or any such consultant, is in violation of the terms thereof.
(b) Upon termination of any employee, the Company will not by reasons of any agreement existing prior to the Closing be liable to such employee for severance pay or any other payments.
(c) No labor strike, grievance, dispute or other labor trouble affecting the Company is pending or, to the knowledge of the Company, threatened. No union or other collective bargaining entity has been certified as representing any employee of the Company; no union organization effort or representation question is pending with respect to the employees of the Company. The Company is not currently engaged in any labor negotiations with any union representing any employees.
6
7
arrangement with any person to sell, transfer or grant participation to such person or to any third person, with respect to any of the Shares.
5. Conditions of SICOR's Obligations at Closing. SICOR's obligations hereunder are subject to the fulfillment on or before the Closing of each of the following conditions:
5.1 Representations and Warranties. The representations and warranties of the Company contained in Section 2 and the representations and warranties of the Senior Managers in Section 3 shall be true, complete and correct as of the Closing with same effect as if made on the Closing Date. The Chief Executive Officer of the Company shall deliver to SICOR at the Closing a certificate certifying that the conditions specified in this Section 5.1 and in Section 5.2 have been fulfilled.
5.2 Performance. The Company and the Senior Managers shall have performed all of their respective obligations hereunder and under the other Transaction Documents which are required to be performed on or prior to the Closing.
8
5.3 Qualifications. All authorizations, approvals or permits, if any, of any governmental authority of the United States or of any U.S. state that are required in connection with the lawful issuance of the Shares pursuant to the Purchase Agreements shall have been duly obtained and be effective as of the Closing.
5.4 Amended and Restated Certificate of Incorporation. Sankyo shall have consented to, and the Company shall have filed (or will concurrently with the Closing hereunder file) with the Secretary of State of the State of Delaware, the Restated Certificate.
5.5 Minimum Investment. The Senior Managers shall have purchased at the Closing an aggregate of at least 10,001,000 shares of Common Stock.
5.6 Sublease Agreement. The Company and SICOR shall have entered into, or concurrently with the Closing hereunder will enter into, the Amendment to Sublease Agreement in the form attached hereto as Exhibit E.
5.7 Novation or Termination. The Company shall have obtained the agreement of each of the counterparties to the contracts listed on Schedule 5.7 attached hereto to effect the novation of such contracts, releasing SICOR from any obligations under such contracts in a manner reasonably acceptable to SICOR, or have given notice of termination to such parties in order to effect a termination of such contracts in accordance with the terms of such contracts.
5.8 Insurance. Except to the extent provided in Section 1.3(a) above, the Company shall have obtained its own employee benefit services (including without limitation health insurance, life insurance, disability insurance, employee assistance program, flex plan, etc.) and its own insurance (including without limitation general liability, product liability and D&O insurance).
5.9 Sankyo Loan Agreement. The Company and Sankyo shall have entered into the Convertible Term Loan Agreement in substantially the form attached hereto as Exhibit F (the "Loan Agreement").
5.10 Amendment to Investor Rights Agreement. The Company, SICOR and Sankyo shall have entered into, or will concurrently with the Closing hereunder enter into, an Amendment to the Investor Rights Agreement in substantially the form attached hereto as Exhibit G (the "Amendment to XXX").
5.11 Research and Development Agreement. The Company and Sankyo shall have entered into, or will concurrently with the Closing hereunder enter into, the Amended and Restated Research and Development and License Agreement in substantially the form attached hereto as Exhibit H (the "Amended and Restated R&D Agreement"), whereby SICOR's obligations under such agreement are terminated in full. Pursuant to the terms of the Amended and Restated R&D Agreement, Sankyo shall have agreed to deliver, within 30 days following the Closing, $2,000,000 to be applied as supplement research funding and a prepayment of development milestones otherwise due the Company thereunder.
5.12 License Agreement. The Company and SICOR shall have entered into, or concurrently with the Closing will enter into, the License Agreement in the form attached hereto as Exhibit I (the "License Agreement").
5.13 Board of Directors. As of the Closing, the Board of Directors shall consist of four persons as follows: Xxxx Xxxxx, Xxxxx X. Xxxx, Xxxx X. Xxxxxxx and Xxxxxxx X. Xxxxxx.
6. Conditions of the Company's Obligations at Closing. The Company's obligations under Section 1.2 hereof are subject to the fulfillment on or before the Closing of each of the following conditions:
6.1 Representations and Warranties. The representations and warranties of the Senior Managers contained in Section 3 hereof and in the Purchase Agreement shall be true, complete and correct as of the Closing with same effect as if made on the Closing Date.
9
6.2 Performance. Each Senior Manager shall have performed all of its obligations hereunder which are required to be performed on or prior to the Closing.
6.3 Qualifications. All authorizations, approvals or permits, if any, of any governmental authority of the United States or of any U.S. state that are required in connection with the lawful issuance of the Shares pursuant to this Agreement shall have been duly obtained and be effective as of the Closing.
6.4 Research and Development Agreement. The Company and Sankyo shall have entered into, or will concurrently with the Closing hereunder enter into, the Amended and Restated R&D Agreement in substantially the form attached hereto as Exhibit H.
6.5 Common Stock Purchase Agreement. The Company and each of the Senior Managers shall have entered into, or will concurrently with the Closing hereunder enter into, a Common Stock Purchase Agreement in substantially the form attached hereto as Exhibit B.
6.6 Payment of the Purchase Price. Each Senior Manager shall have delivered the Purchase Price for such Senior Manager's Shares.
(a) The Company shall indemnify, defend and hold harmless SICOR from and against any and all losses, liabilities, damages and expenses (including reasonable attorneys' fees and costs) (collectively, the "Liabilities") incurred or suffered by SICOR to the extent arising from (i) termination of the Transition Services Agreement in accordance with Section 1.3(a) hereof, (ii) the Company's agreements and arrangements with its employees and consultants, (iii) the Company's Plans, (iv) the contracts listed on Schedule 5.7, the License and Royalty Agreement (the "Pfizer License Agreement") and the Collaborative Research Agreement, each effective as of May 1, 1996, as amended, between Pfizer, Inc. and SICOR, and any contract to which the Company is a party, (v) the Severance Agreement dated as of September 23, 1996 between Xxxx X. Xxxxxxxx and SICOR, as amended (vi) any breach of any representation, warranty or covenant of the Company under this Agreement or (vi) any action, or omission to act, of the Company subsequent to the Closing, other than losses, liabilities, damages and expenses arising from the gross negligence or willful misconduct of SICOR. "Plan" means (a) any "employee benefit plan" within the meaning of Section 3(3) of ERISA, (b) any profit sharing, pension, deferred compensation, bonus, stock incentive, stock option, stock purchase, stock appreciation right, severance, retainer, consulting, health or incentive plan or agreement, (c) any plan or policy providing for "fringe benefits" (including without limitation vacation, paid holidays, personal leave, educational benefit or similar programs) to employees and (d) any employment agreement. Notwithstanding the foregoing, the Company shall not indemnify SICOR for any Liabilities incurred as a result of any claim brought by Pfizer, Inc. as a result of SICOR and the Company entering into the License Agreement.
(b) If SICOR intends to claim indemnification under this Section 7 with respect to any claim, demand, action or other proceeding by any third party, SICOR promptly shall notify the Company thereof, and the Company shall have the right to assume and control the defense and any settlement thereof with counsel selected by the Company; provided, however, that SICOR shall have the right to retain its own counsel, with the fees and expenses to be paid by the Company, if representation of SICOR by the counsel retained by the Company would be inappropriate due to actual or potential differing interests between SICOR and any other party represented by such counsel in such proceedings.
(c) The indemnity obligations under this Section 7 shall not apply to amounts paid by SICOR in settlement of any claim, demand, action or other proceeding if such settlement is effected without the consent of the Company, which consent shall not be unreasonably withheld or delayed. The failure to deliver notice to the Company within a reasonable time after the commencement of
10
any such action or other proceeding, if prejudicial to its ability to defend such action, shall relieve the Company of any liability to SICOR under this Section 7, but the omission so to deliver notice to the Company will not relieve it of any liability that it may have to SICOR otherwise than under this Section 7.
(d) SICOR, its employees and agents, shall reasonably cooperate with the Company and its legal representatives in the investigation of any claim, demand, action or other proceeding covered by this indemnification.
8.2 Delivery of Financial Statements.
(a) For so long as SICOR owns any shares of the capital stock of the Company, the Company shall deliver to SICOR and each assignee of SICOR who acquires (i) all of SICOR's shares of Subordinated Preferred Stock or (ii) an aggregate amount of Common Stock and Preferred Stock which together represent at least ten percent (10%) of the aggregate amount of Common Stock then outstanding and the Common Stock issuable upon conversion of the then outstanding Preferred Stock:
(i) as soon as practicable, but in any event within ninety (90) days after the end of each fiscal year of the Company, a statement of operations for such fiscal year, a balance sheet of the Company as of the end of such year, and a statement of cash flows for such year, such year-end financial reports to be in reasonable detail, prepared in accordance with generally accepted accounting principles ("GAAP"), and audited and certified by independent public accountants of nationally recognized standing selected by the Company;
(ii) as soon as practicable, but in any event within forty-five (45) days after the end of each of the first three quarters of the fiscal year, the Company's unaudited statement of operations, statement of cash flows and balance sheet for and as of the end of such quarter;
(iii) within thirty (30) days of the end of each month, an unaudited statement of operations, statement of cash flows and balance sheet for and as of the end of such month, in reasonable detail; such monthly statements shall also contain the foregoing information on a year-to-date basis and shall also compare actual performance to budget;
(iv) within sixty (60) days prior to the close of each fiscal year, a comprehensive operating budget for the next fiscal year forecasting the Company's revenues, expenses and cash position, prepared on a monthly basis, including balance sheets and statements of cash flows for such months and, as soon as prepared, any other budgets or revised budgets prepared by the Company; and
(v) such other information relating to the financial condition, business, prospects or corporate affairs of the Company as SICOR or any such assignee of SICOR may from time to time request; provided, however, that the Company shall not be obligated pursuant to this Section 8.2 to provide access to any information which it reasonably considers to be a trade secret, confidential or of a nature providing a competitive advantage.
11
such financial were prepared in accordance with internally consistent accounting methods consistently applied with prior practice for earlier periods and fairly present the financial condition of the Company and its results of operations for the period specified, subject to year-end audit adjustment.
12
will provide to SICOR a status report on the last day of each calendar month regarding the Company's actions taken in this regard.
9.2 Governing Law; Arbitration. (a) This Agreement shall be governed by and construed under the laws of the State of California (irrespective of its choice of law principles).
(b) Any disputes arising between the Parties relating to, arising out of or in any way connected with this Agreement or any term or condition hereof, or the performance by any Party of its obligations hereunder, shall be promptly presented to the chief executive officers of the Parties for resolution and if the chief executive officers cannot promptly resolve such disputes, then such dispute shall be finally resolved by arbitration. Whenever a Party shall decide to institute arbitration proceedings, it shall give written notice to that effect to other Parties. The Party giving notice shall refrain from instituting the arbitration proceedings for a period of sixty (60) days following such notice. Any arbitration hereunder shall be conducted pursuant to the Rules of Arbitration of the International Chamber of Commerce. Each such arbitration shall be conducted in the English language by a panel of three arbitrators appointed in accordance with such rules (with SICOR and the Company, on the one hand, and Senior Managers, on the other hand, respectively having the right to appoint one arbitrator). Any such arbitration shall be held in Los Angeles, California. The arbitrators shall have the authority to grant specific performance, and to allocate between the Parties the costs of arbitration in such equitable manner as they determine. Judgment upon the award so rendered may be entered in any court having jurisdiction or application may be made to such court for judicial acceptance of any award and an order of enforcement, as the case may be.
The Company agrees to indemnify and hold harmless Senior Managers from any liability for any commission or compensation in the nature of a finders' fee (and the costs and expenses of defending against such liability or asserted liability) for which the Company or any of their respective officers, employees or representatives is responsible.
13
provided, however, that the Company will reimburse the reasonable fees and expenses of Xxxxxx Xxxxxxx Xxxxxxxx & Xxxxxx, counsel to the Senior Managers, payable at the Closing upon receipt of such counsel's invoice therefor. If any action at law or in equity is necessary to enforce or interpret the terms of any of the Transaction Documents, the prevailing Party shall be entitled to reasonable attorneys' fees, costs and necessary disbursements in addition to any other relief to which such Party may be entitled.
No provision hereof is intended to confer upon any Person other than the Parties any rights or remedies hereunder.
10. California Commissioner of Corporations. THE SALE OF THE SECURITIES WHICH ARE THE SUBJECT OF THIS AGREEMENT HAS NOT BEEN QUALIFIED WITH THE COMMISSIONER OF CORPORATIONS OF THE STATE OF CALIFORNIA AND THE ISSUANCE OF SUCH SECURITIES OR THE PAYMENT OR RECEIPT OF ANY PART OF THE CONSIDERATION THEREFOR PRIOR TO SUCH QUALIFICATION IS UNLAWFUL, UNLESS THE SALE OF SECURITIES IS EXEMPT FROM QUALIFICATION BY SECTION 25100, 25102 OR 25105 OF THE CALIFORNIA CORPORATIONS CODE. THE RIGHTS OF ALL PARTIES TO THIS AGREEMENT ARE EXPRESSLY CONDITIONED UPON SUCH QUALIFICATION BEING OBTAINED, UNLESS THE SALE IS SO EXEMPT.
14
| METABASIS THERAPEUTICS, INC. | ||
| By | /s/ XXXX X. XXXXXXX | |
| Its | Chairman and CEO | |
| Address: 0000 Xxxxx Xxxxxx Xxxxx Xxx Xxxxx, XX 00000 | ||
| SICOR INC. | ||
| By | /s/ [ILLEGIBLE] | |
| Its | Exec. VP Finance | |
| Address: 00 Xxxxxx Xxxxxx Xxxxxx, XX 00000 With a copy to: Pillsbury Madison & Sutro LLP 000 Xxxxxxxxxx Xxxxxx Xxx Xxxxxxxxx, XX 00000 Attention: Xxxxxx X. Xxxxxx, Xx. |
COUNTERPART SIGNATURE PAGE MASTER AGREEMENT
| SENIOR MANAGERS: | ||
| /s/ XXXX XXXX Xxxx Xxxx | ||
| Address: | 0000 Xxxxxxxxxxx Xxxx Xxxxxxxxx, XX 00000 | |
| /s/ XXXX XXXXX Xxxx Xxxxx | ||
| Address: | 00000 Xxxxx Xx. Xxx Xxx, XX 00000 | |
| /s/ XXXX X. XXXXXXX Xxxx X. Xxxxxxx | ||
| Address: | 0000 Xxxxx Xxxxxxx Xxxxxx Xxx Xxxxx, XX 00000 |
LIST OF EXHIBITS
| EXHIBIT A | AMENDED AND RESTATED CERTIFICATE OF INCORPORATION | |
| EXHIBIT B | COMMON STOCK PURCHASE AGREEMENT | |
| EXHIBIT C | NOTE | |
| EXHIBIT D | EMPLOYEE'S PROPRIETARY INFORMATION AND INVENTIONS AGREEMENT | |
| EXHIBIT E | AMENDMENT TO SUBLEASE AGREEMENT | |
| EXHIBIT F | LOAN AGREEMENT | |
| EXHIBIT G | AMENDMENT TO INVESTOR RIGHTS AGREEMENT | |
| EXHIBIT H | AMENDED AND RESTATED RESEARCH AND DEVELOPMENT AGREEMENT | |
| EXHIBIT I | LICENSE AGREEMENT |
LIST OF SCHEDULES
| Schedule 1.1(b) | Senior Manager Purchase Schedule | |
| Schedule 1.3(b) | Schedule of Senior Manager Options | |
| Schedule 2 | Schedule of Exceptions | |
| Schedule 5.7 | Contracts for Novation Prior to Closing | |
| Schedule 8.7 | Contracts for Novation/Termination Post-Closing |
SCHEDULE 1.1(b)
Schedule of Senior Managers
| Amount Payable in Cash | Amount Payable in Full Recourse Promissory Note | Amount Payable in Non-Recourse Promissory Note | Total Purchase Price | Number of Shares Purchased | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Xxxx Xxxx | $ | 11,383.93 | $ | 64,516.52 | — | $ | 75,900.45 | 1,518,009 | ||||||
| Xxxx Xxxxx | $ | 30,133.93 | — | $ | 170,779.02 | $ | 200,912.95 | 4,018,259 | ||||||
| Xxxx X. Xxxxxxx | $ | 33,482.14 | — | $ | 189,754.46 | $ | 223,236.60 | 4,464,732 | ||||||
| TOTAL | $ | 75,000 | $ | 64,516.52 | $ | 360,533.48 | $ | 500,050.00 | 10,001,000 |
SCHEDULE 1.3(b) SCHEDULE OF SENIOR MANAGEMENT OPTIONS
Metabasis Therapeutics, Inc. Stock Option Plan Summary
CONFIDENTIAL
| Vesting Calculations Through: 8/16/99 | |||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Holder | Option Type | Vesting Type | Status | Grant Date | Vesting Start Date | Expiration Date | Date Exer. /Ret. | Exercise Price | Granted | Exercised | Returned | Outstanding | Vested August 16, 1999 | Unvested August 16, 1999 | |||||||||||||||||
| Xxxx | Xxxx | ISO | Initial | Employee | 4/7/98 | 4/7/98 | 4/6/08 | $ | 0.500 | 35,000 | 35,000 | — | — | — | |||||||||||||||||
| Xxxx | Xxxx | ISO | Perf/Prom | Employee | 4/7/98 | 4/7/98 | 4/6/08 | $ | 0.500 | 7,000 | 7,000 | — | — | — | |||||||||||||||||
| Xxxx | Xxxxx | ISO | Initial | Employee | 4/7/98 | 4/7/98 | 4/6/08 | $ | 0.500 | 186,666 | 186,666 | — | — | — | |||||||||||||||||
| Xxxx | Xxxxxxx | ISO | Initial | Employee | 4/7/98 | 4/7/98 | 4/6/08 | $ | 0.500 | 206,666 | 206,666 | — | — | — | |||||||||||||||||
| 435,332 | 435,332 | — | — | — |
Schedule 2 Schedule of Exceptions
EXHIBIT SCHEDULE OF EXCEPTIONS
This Schedule of Exceptions, dated as of June 30, 1999 is made and given pursuant to Section 5.1 of that certain Master Agreement (the "Agreement"), dated of even date herewith, by and among Metabasis Therapeutics, Inc. ("MTI"), SICOR, Inc. ("SI") and each of Xxxx Xxxx, Xxxx Xxxxx and Xxxx Xxxxxxx (collectively, the "Senior Managers").
The section numbers in this Schedule of Exceptions correspond to the section numbers in the Agreement; however, any information disclosed herein under any section number shall be deemed to be disclosed and incorporated into any other section number under the Agreement where such disclosure would be appropriate. Any terms defined in the Agreement shall have the same meaning when used in this Schedule of Exceptions as when used in the Agreement unless the context otherwise requires.
Informal discussions have been held with MTI's sole outside Director, Xxxxx Xxxx, regarding the consideration to be paid to Xx. Xxxx in exchange for his continued participation on MTI's board. While no formal agreement has been reached, Xx. Xxxx has agreed in principal to continue to contribute his services to MTI in exchange for a future grant of MTI options in amounts and on terms customarily extended to directors of development stage biopharmaceutical companies.
The various Amendments to the Master Lease Agreement between COMDISCO and SI contain certain covenants requiring the maintenance of certain financial ratios and minimal asset values. In July 1998 the Master Lease Agreement was amended to name MTI as a subsidiary of SI and a separate Lessor under the Agreement. The covenants continue to apply to SI. MTI does not have the ability to determine if SI is in compliance with these covenants and consequently is unaware of any violation.
MTI has not paid the minimum annual royalty payment currently due under the License Agreement dated June 12, 1987 between Gensia Pharmaceuticals Inc., and the Regents of the University of California which was transferred to MTI in December 1997. MTI intends to terminate the license and pay the past due royalty upon receipt of the written denial. Borrower's request for a deferral of such payment has been denied by the University. Borrower will either pay the $25,000 minimum annual royalty or terminate the license.
1
MTI has agreed to pay SI certain royalty payments with respect to certain intellectual property rights pursuant to the terms of the Master Agreement (the "Master Agreement") between the parties of even date herewith.
MTI is currently in discussions with COMDISCO to provide for extension financing for material residual payments required under certain lease schedules which have reached the ends of their respective initial lease terms. Due to the timing of the MTI restructuring plan the decision to request extension financing, to pay the residual, or to return the equipment was not made by MTI within the time frame required under the Master Lease Agreement.
Section 2.6(a)
Xxxx Xxxxx Promissory Note Xxxx Xxxxxxxx Promissory Note
As a result of the December 1997 Asset and Liability Transfer an asset labeled "Xxxx Xxxxxxx Travel Advance" of $5,000 was transferred to the books of MTI. The asset remains on MTI's books without supporting documentation—SI and MTI are researching. Xx. Xxxxxxx has asserted that he does not have any unpaid travel advances to SI or MTI.
Metabasis Severance Agreement—X. Xxxxxxx Metabasis Severance Agreement—X. Xxxxxxxx Metabasis Severance Agreement—X. Xxxx Metabasis Severance Agreement—X. Xxxxx
Informal discussions have been held with MTI's sole outside Director, Xxxxx Xxxx, regarding the consideration to be paid to Xx. Xxxx in exchange for his continued participation on MTI's board. While no formal agreement has been reached, Xx. Xxxx has agreed in principal to continue to contribute his services to MTI in exchange for a future grant of MTI options in amounts and on terms customarily extended to directors of development stage biopharmaceutical companies.
Section 2.6(b)
Sankyo R&D and license agreements Pfizer R&D and license agreements Santen testing agreement Bayer testing agreement UCSD Duke COMDISCO leases Toshiba lease BCL capital lease Signal sublease Consultants—Wakabyashi Consultants—Xxxxxx Research Contracts—University of Pittsburgh (Kochanek) Research Contracts—Utah State University (Xxxxxxx) Marketing Study—Xxxxx and Associates
2
Section 2.6(c)
Xxxx Xxxxx Promissory Note Xxxx Xxxxxxxx Promissory Note
Section 2.6(d)
The Company has held preliminary business combination discussions with Metabolex, Inc. The last such meeting was held in March. No actions to date have been taken in contemplation of entering into such a combination.
2.7 Patents and Trademarks
Sankyo R&D and license agreements Pfizer R&D and license agreements Santen testing agreement Bayer testing agreement Letter from University of Virginia re: alleged infringement of certain patents Letter from Wistar Institute re: alleged infringement of certain patents Letter from ITC Pharmaceuticals re: alleged infringement of certain patents
(2.8) Employee Matters
(b)
Metabasis Severance Agreement—X. Xxxxxxx Metabasis Severance Agreement—X. Xxxx Metabasis Severance Agreement—X. Xxxxxx Metabasis Severance Agreement—X. Xxxxxxx Metabasis Severance Agreement—X. Xxxxx Metabasis Severance Agreement—J. Soelbach
(2.9) Employee Benefit Plans
The Company provides a 401(k) plan to its employees.
(2.10) Permits
MTI has applied for, but not yet received, its San Diego City Business License
(2.14) Cash Resources
MTI's projections are dependent on the timely infusion of Sankyo capital in accordance with the Term Loan and Amended and Restated R&D Agreements. Such projections constitute forward-looking statements themselves (and contain forward-looking statements), which inherently involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of MTI, or industry results, to be materially different from any future results, performance or achievements expressed or implied in such forward-looking statements. Undue reliance should not be placed on such forward-looking statements.
MTI's projections are dependant on the continuation of its current operating environment and may be adversely impacted by unforeseen events beyond its control.
Due to the nature of its business, MTI does not specifically carry product liability and professional errors and omissions coverage.
3
(2.16) Environmental and Safety Laws
MTI underwent a routine inspection on October 22, 1998 by the San Diego County Hazardous Materials Management Division and was found to be in violation of certain "storage and handling" provisions of the California Code of Regulations, the Health and Safety Code and/or the San Diego County Code. The Company has taken corrective action and communicated the same to the County and anticipates no additional action against it.
4
Schedule 5.7 Contracts for Novation or Termination Prior to Closing
Agreement for Services dated November 28, 1995 among Synteract, Inc., Xxxxxxxx Xxxxx and Metabasis (as assignee of SICOR).
[METABASIS THERAPEUTICS LETTERHEAD]
June 28, 1999
Xx. Xxxxx Xxxxxx President Synteract, Inc. 000 Xxxxx Xxxxxxxxx Xxxxxxxxx, XX 00000
Dear Xxxxx:
This letter is to inform you that we wish to terminate the Agreement for Services dated November 28, 1995, between Synteract, Inc. and Xxxxxxxx Xxxxx, and Metabasis Therapeutics, Inc. (as assignee of SICOR, Inc., formerly known as Gensia, Inc.).
This termination is made in accordance with Section 7 of the subject agreement and in no way effects the Agreement dated January 19, 1999 between Synteract, Inc., and Metabasis Therapeutics, Inc.
Sincerely
/s/ XXXX X. XXXXXXX Xxxx X. Xxxxxxx, Ph.D. Chairman and CEO
PKL/asd
Schedule 8.7 Contracts for Novation or Termination Post-Closing
Schedule Nos. EG-34, EG-35, EG-36 and EG-37, each dated September 1, 1998 between Comdisco, Inc. and the Company to that certain Master Lease Agreement dated as of March 30, 1994 between Comdisco, Inc. and SICOR.
License Agreement dated June 12, 1987 between The Regents of the University of California and the Company (as assignee of SICOR).
License Agreement dated April 22, 1988 between Duke University and the Company (as assignee of SICOR).
Research and Development Agreement dated December 31, 1991 between the Company (as assignee of SICOR) and Sandoz Pharmaceuticals Corporation.
License Agreement with the University of South Alabama.
Testing Agreement dated August 21, 1996 between the Company (as assignee of SICOR) and Santen.
Testing Agreement with Alcon Laboratories.
EXHIBIT A Amended and Restated Certificate of Incorporation
EXHIBIT B Common Stock Purchase Agreement
EXHIBIT C Note
EXHIBIT D Employee's Proprietary Information and Inventions Agreement
EXHIBIT E Amendment to Sublease Agreement
EXHIBIT F Loan Agreement
EXHIBIT G Amendment to Investor Rights Agreement
EXHIBIT H Amended and Restated Research and Development Agreement
EXHIBIT I License Agreement
MASTER AGREEMENT
